Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice
Table 6
Factors associated with survival in patients with glioblastoma.
Factor
Log rank test P-value1
Hazard ratio
95% Confidence interval
P-value
Age at diagnosis (years)2
< 0.0001
1.02
1.01, 1.03
0.00015
Extent of surgery (Ref: Biopsy)
< 0.0001
Resection
0.52
0.40, 0.67
< 0.0001
Unknown
0.63
0.35, 1.13
0.12
Radiation dose (Ref: No radiotherapy)
< 0.0001
60 Gy
0.67
0.48, 0.93
0.015
< 60 Gy
0.98
0.66, 1.46
0.93
Unknown
0.90
0.54, 1.48
0.67
Chemotherapy (Ref: No chemotherapy)
< 0.0001
Temozolomide and bevacizumab
0.32
0.22, 0.49
< 0.0001
Temozolomide without bevacizumab
0.58
0.41, 0.82
0.0018
Non-temozolomide agents only
0.68
0.46, 1.01
0.054
Charlson comorbidity score2
0.049
1.06
0.99, 1.13
0.12
Tumor located in occipital region – Yes/No (Ref: No)
0.0044
1.33
0.95, 1.86
0.10
Tumor located in corpus callosum – Yes/No (Ref: No)
0.00066
1.27
0.90, 1.79
0.17
Age at diagnosis and Charlson comorbidity score were categorized to perform the log rank test. For age at diagnosis, two categories were compared: < 65 years and ≥ 65 years. For Charlson comorbidity score, three categories were compared: 0, 1-2, and ≥ 3. Age at diagnosis and Charlson comorbidity score were continuous variables in the Cox proportional hazards regression model.
